蓝帆医疗最新公告：子公司Lithonic冠脉血管内冲击波治疗系统获得CE证书

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic coronary intravascular shockwave treatment system, which is designed for pre-treatment of severely calcified stenosis, reducing the risk of complications such as vascular perforation and no-reflow [1] Group 1 - The CE certification signifies international recognition of the technology [1] - This certification reinforces the company's technological advantage in the coronary field [1] - The expected positive impact on the company's operational development [1] Group 2 - The sales of medical devices are influenced by market conditions [1] - Investors are advised to exercise caution in their investments [1]